From the MeOH extract of Vietnamese Caesalpinia sappan, a novel biogenetically exclusive benzindenopyran, with a new carbon framework, neoprotosappanin (1), and a new compound, protosappanin A dimethyl acetal (3), were isolated together with protosappanin E-2 (2), neosappanone A (4), and 13 previously reported phenolic compounds (5-17). Their structures were elucidated on the basis of spectroscopic data. Compounds 1-4, 7, 13, and 15-17 showed significant xanthine oxidase inhibitory activity in a concentration-dependent manner, and sappanchalcone (17) showed the most potent activity with an IC 50 value of 3.9 m mM, comparable to that of positive control allopurinol (IC 50 , 2.5 m mM). The kinetic study of these inhibitors indicated that they are competitive inhibitors, the same as allopurinol, except for 1 and 16 which are noncompetitive inhibitors.
Xanthine oxidase (XO) is a key enzyme that catalyses the oxidation of xanthine and hypoxanthine into uric acid, 1) and plays a vital role in producing hyperuricemia and gout. Allopurinol is a clinically used XO inhibitor in the treatment of gout, which blocks the terminal step in uric acid biosynthesis can lower the plasma uric acid concentration.
2) However, due to unwanted side effects of allopurinol, such as hepatitis, nephropathy, and allergic reactions, new alternatives with increased therapeutic activity and less side effects are desired. Moreover, superoxide anion radicals generated by XO are involved in various pathological states such as hepatitis, inflammation, aging, carcinogenesis, and ischemia-reperfusion.
3) Thus, the search for novel XO inhibitors would be beneficial not only to treat gout but also to combat various other diseases.
The heartwood of Caesalpinia sappan L. (Caesalpiniaceae) has been used in Vietnamese traditional medicine for the treatment of rheumatism and inflammatory diseases and as an emmenagogue and homeostatic agent. 4) Our preliminary screening study revealed that the methanolic extract of the heartwood of C. sappan exhibited significant XO inhibitory activity with an IC 50 value of 14.2 mg/ml. 5) Therefore, we carried out fractionation of the MeOH extract and isolated a dibenzoxocin possessing a novel carbon skeleton named neosappanone A (4), which was reported in our preliminary communication. 6) Further investigation on this active MeOH extract led to the isolation of 16 additional phenolic compounds including a new benzindenopyran, neoprotosappanin (1) having a novel carbon framework, protosappanin E-2 (2), and protosappanin A dimethyl acetal (3) . In this paper, we report the isolation and structure elucidation of these compounds by spectroscopic techniques, together with the XO inhibitory activity of the isolated compounds.
Results and Discussion
The dried heartwood of C. sappan was extracted with refluxing MeOH, and the MeOH extract was fractionated with EtOAc to yield EtOAc-soluble fraction. The EtOAc-soluble fraction showed XO inhibitory activity with an IC 50 value of 12.8 mg/ml. Further separation and purification of this fraction led to the isolation of new compounds 1 and 3, together with neosappanone A (4).
6) The known compounds were identified by analysis of their spectroscopic data and comparison with literature data to be protosappanin E-2 (2), 7) protosappanin B (5), 8) protosappanin C dimethyl acetal (6), 9) protosappanin A (7), 10) brazilin (8), 11) 3Ј-O-methylbrazilin (9), 12) 3Ј-deoxysappanol (10), 13, 14) 3Ј-deoxy-4-O-methylsappanol (11), 15) 4-O-methylsappanol (12), 12, 16) sappanol (13), 15) 4-Omethylepisappanol (14) , 12, 16) sappanone B (15), 12, 15) 3-deoxysappanone B (16), 12, 16) and sappanchalcone (17) . 17) Neoprotosappanin (1) This suggested that the two singlets in unit II should be para to each other. Thus, the linkage between units I and II should be via C-7 in unit I and C-2 in unit II, which was confirmed by the HMBC correlations of H-7 in unit I with C-1, C-2, and C-3 in unit II (Fig. 1) . The relative stereochemistry at C6a and C-11b in each brazilin monomer unit should be the same as those of 8 by comparision of its spectroscopic data and literature data, 11, 18) as well as biogenetic consideration. Further, the rotating frame nuclear Overhauser effect spectroscopy (ROESY) correlations between H-7 and H-11b in unit I indicated that H-7 to be b-oriented (Fig. 1) . Thus, the structure of neoprotosappanin was concluded as 1.
Protosappanin E-2 (2) was obtained as a yellow amorphous solid. Its molecular formula was determined by HR-FAB-MS to be C 32 H 26 O 11 . The IR spectrum of 2 showed the absorptions due to hydroxyl (3300 cm Table 2 ). The 13 C-NMR spectrum showed 32 carbon signals including three oxygenated quaternary carbons and 24 aromatic carbons ( Table 2 ). Analysis of the 1 H-NMR spectrum indicated two distinct groups of signals ascribable to protosappanin B (unit I) and brazilin (unit II) moieties. However, it showed slight difference in the 1 H-NMR spectral data due to presence of an acetal methine at d 5.0 instead of an oxymethylene at d 3.53 in protosappanin B (5), and the disappearance of signal due to an aliphatic methine in brazilin (8), respectively. Furthermore, its 13 C-NMR spectrum displayed one more acetal carbon instead of an oxymethylene carbon in 5, and oxygenated quaternary carbon instead of an aliphatic methine carbon in 8. These data indicated that the protosappanin B moiety should be linked to brazilin moiety via the acetal carbon C-13 (d 108.2). Further HMBC correlations (Fig. 2 ) of H-13 (d 5.0) (unit I) with C-6aЈ (d 73.1) and C-11bЈ (d 88.9) (unit II) led to the complete assignment of the linkage between unit I and unit II. In the ROESY experiment, the significant correlations H-13/H6Јb and H-13/H-6b suggested that they orientate on the same side. Analysis of these ROESY correlations by means of the Drieding stereomodel indicated that the hydroxyl group at C-7 should be a-oriented. Literature survey of the compound with the structure indicated that 2 should be protosappanin E-2, having R configuration at C-13. 7) Because protosappanin E-2 has been previously reported only as an inseparable mixture with E-1, their spectroscopic data has not been reported. Thus, this is the first report of the isolation and spectral data of protosappanin E-2 (2).
The HR-FAB-MS of compound 3 showed a quasimolecular ion at m/z 341.1001 [MϩNa] ϩ , consistent with the molecular formula C 17 H 18 O 6 . The IR spectrum of 3 displayed the absorbance of hydroxyl (3300 cm
Ϫ1
) and phenyl (1600, 1445 cm Ϫ1 ) groups. The 1 H-NMR spectrum of 3 revealed signals due to two methoxyl, an oxymethylene, an aliphatic methylene, two singlets of a 1,2,4,5-tetrasubstituted benzene ring, and three aromatic protons consisting of an ABX system (Table 2 ). In addition, its 13 Table 2) . These data were similar to those of protosappanin A (7), 10) isolated from the same extract, but they were characterized by the appearance of signals of two methoxyl groups and an acetal carbon and disappearance of the signal of a ketone carbonyl carbon in 7. Thus, 3 was assumed to be protosappanin A dimethyl acetal, which was confirmed by the HMBC spectrum and the fact that an acid treatment of 3 gave 7.
In this paper, we have identified a novel benzindenopyran, neoprotosappanin (1) and a novel dibenzoxocin, protosappanin A dimethyl acetal (3), and protosappanin E-2 (2) together with 14 known phenolic compounds (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . To the best of our knowledge, 1 represents a novel carbon framework, a benzindenopyran system, produced from two monomeric units, brazilin (8), while 3 might be an artifact formed from 7 during isolation procedure as demonstrated by the reverse reaction.
The isolated compounds were tested for their XO inhibitory activity (Table 3 ). The assay was carried out at five different concentrations ranging from 0.2-100 mM, and compounds 1-4, 7, 13, and 15-17 displayed significant dose-dependent inhibition. Sappanchalcone (17) displayed the most potent activity with an IC 50 value of 3.9 mM (Fig. 3) , comparable to that of allopurinol (IC 50 , 2.5 mM), a well known XO inhibitor clinically used for treatment of gout. Further literature survey revealed that this is the first report of chalcone on XO inhibitory activity. This suggests the need for further exploration of chalcones as the natural XO inhibitors for the possible health benefit in the treatment of 986 Vol. 53, No. 8 , those having dimethyl acetal (3) or carbonyl functionality (7) at C-3 were more active than others (3≈7ϾϾ5≈6). Brazilin-type monomers such as 8 and 9 were inactive, but the potency of XO inhibitory activity was significantly increased by the combination of two brazilin units or the brazilin unit with another dibenzoxocin (2Ͼ1Ͼ3≈7ϾϾ5≈6). However, the dimeric dibenzoxocin 4 with two similar units showed moderate inhibitory activity (2Ͼ4Ͼ1). The benzopyranol-type compounds 10-14 displayed only weak inhibitory activity, while benzopyranones showed significantly improved activity (15≈16ϾϾ12-14). Further kinetic studies indicated 2, 3, 4, 7, 13, 15, and 17 to be competitive inhibitors, the same as allopurinol, while 1 and 16 were noncompetitive inhibitors with respect to the substrate, xanthine. The inhibition constants (K i ) were determined from the slopes of the Lineweaver-Burk plot for competitive inhibition, and intercept on vertical axis for noncompetitive inhibition (Fig. 4) and are listed in Table 3 . Thus, the traditional use of C. sappan for the treatment of rheumatism and inflammatory diseases in Vietnam could be attributable to the XO inhibitory activity of phenolic constituents such as 17.
Experimental
General Experimental Procedures Optical rotations were recorded on a JASCO DIP-140 digital polarimeter. IR spectra were measured with a Shimadzu IR-408 spectrophotometer in CHCl 3 solutions. NMR spectra were taken on a JEOL JNM-LA400 spectrometer with tetramethylsilane (TMS) as an internal standard, and chemical shifts are expressed in d values. HR-FAB-MS measurements were carried out on a JEOL JMS-700T spectrometer, and glycerol was used as a matrix. Column chromatography was performed with BW-820MH Si gel (Fuji Silisia, Aichi, Japan). Analytical and preparative TLC were carried out on precoated Merck Kieselgel 60F 254 Extraction and Isolation The dried heartwood of C. sappan was crushed into a powder and the powder (2.5 kg) was extracted with MeOH (12 l, reflux, 3 h, ϫ3) to yield a MeOH extract (300 g; IC 50 , 16.9 mg/ml). The extract was partitioned between EtOAc and water to give an EtOAc-soluble fraction (170 g; IC 50 , 12.8 mg/ml). The EtOAc-soluble fraction (100 g) was subjected to silica gel column chromatography with MeOH-CHCl 3 to give seven fractions: fr. 1, 5% MeOH-CHCl 3 eluate, 4.1 g; fr. 2, 7% MeOH-CHCl 3 eluate, 1.4 g; fr. 3, 8% MeOH-CHCl 3 eluate, 9.4 g; fr. 4, 9% MeOH-CHCl 3 eluate, 7.6 g; fr. 5, 12% MeOH-CHCl 3 eluate, 40 g; fr. 6, 15% MeOH-CHCl 3 eluate, 19.7 g; fr. 7, 20% MeOH-CHCl 3 eluate, 14 g. These fractions were examined for XO inhibitory activity, and active fractions were subjected to the further separation.
Fraction 2 (IC 50 , 19.5 mg/ml) was rechromatographed on silica gel with MeOH-CHCl 3 , followed by reversed-phase preparative TLC with CH 3 CN : MeOH : H 2 Oϭ1 : 1 : 3, to give protosappanin A (7, 10.9 mg), 10) brazilin (8, 4.6 mg), 11) 3Ј-O-methylbrazilin (9, 2.9 mg), 12) 3Ј-deoxysappanol (10, 1.9 mg), 13, 14) 3Ј-deoxy-4-O-methylsappanol (11, 2.5 mg), 15) and 4-Omethylsappanol (12, 11.6 mg). 12, 16) Fraction 3 (IC 50 , 8.5 mg/ml) was further separated by silica gel comlumn chromatography, followed by reversed-phase preparative TLC with CH 3 CN : MeOH : H 2 Oϭ1 : 1 : 3, to give neosappanone A (4, 3.3 mg), protosappanin A dimethyl acetal (3, 15.2 mg), 7 (21.6 mg), 8 (4.6 mg), 12 (23.7 mg), sappanol (13, 1.4 mg), 15) 4-O-methylepisappanol (14, 6.9 mg), 12, 16) 12, 16) and sappanchalcone (17, 13.0 mg).
17)
Fraction 4 (IC 50 , 11.9 mg/ml) was rechromatographed on silica gel with MeOH-CHCl 3 , followed by reversed-phase preparative TLC with CH 3 CN : MeOH : H 2 Oϭ1 : 1 : 3, to yield 8 (17.2 mg), 13 (3.9 mg), 14 (2.5 mg), and 16 (16.8 mg) .
Fraction 5 (IC 50 , 10.9 mg/ml) was subjected to silica gel comlumn chromatography with MeOH-CHCl 3 , followed by reversed-phase preparative TLC with CH 3 CN : MeOH : H 2 Oϭ1 : 1 : 3, to give protosappanin E-2 (2, Other compounds showed only weak inhibitory activity at 100 mM, and thus are excluded in this Table. Fig 5 mg) , 7) protosappanin B (5, 19.7 mg), 18) and protosappanin C dimethyl acetal (6, 8.6 mg Acid Treatment of 3 Compound 3 (3.0 mg) was treated with triflouroacetic acid (50 ml) in THF (2 ml) at room temperature for 3 h, followed by neutralization with sodium bicarbonate. The reaction mixture was extracted with ether and dried over anhydrous MgSO 4 . The crude product was purified by preparative TLC with MeOH-CHCl 3 (1 : 9) to give 7.
XO Inhibitory Assay The XO inhibitory activity was assayed spectrophotometrically at 290 nm under aerobic conditions by using 96-well plates as described previously.
6) XO inhibitory activity was expressed as the percentage inhibition of XO in the above assay system, calculated as (1ϪB/A)ϫ100, where A and B are the activities of the enzyme without and with test material. IC 50 values were calculated from the mean values of data from four determinations.
Lineweaver-Burk Plots To determine the mode of inhibition by active compounds from the plant, Lineweaver-Burk plot analysis was performed. This kinetics study was carried out in the absence and presence of active compounds with varying concentrations of xanthine as substrate. The initial rates were determined on the basis of the rate of increase in absorbance at 290 nm between 0.5 and 3 min. The data represent the meanϮS.D. of four determinations. The inhibition constants (K i ) were determined from the slopes of the Lineweaver-Burk plot for competitive inhibition, and intercept on vertical axis for noncompetitive inhibition.
